Elidan J, Levi H, Cohen E, BenEzra D
Department of Otolaryngology, Hadassah University Hospital, Jerusalem, Israel.
Ann Otol Rhinol Laryngol. 1991 Jun;100(6):464-8. doi: 10.1177/000348949110000607.
Thirty-five patients with Behçet's disease (20 under cyclosporine A [CyA] treatment and 15 under the conventional therapy), 12 patients suffering from endogenous uveitis, and 35 normal subjects were evaluated audiologically before entering the study and were followed up for at least a year. Twenty-eight Behçet patients (80%) showed some degree of hearing loss. The averaged pure tone audiogram of the Behçet group showed statistically significant auditory deficits in comparison with that of the control group. None of either the Behçet group or the uveitis group showed any hearing deterioration during the follow-up period. Five Behçet patients under CyA therapy demonstrated improvement in their hearing. The difference between the two groups of Behçet patients (CyA versus conventional treatment) was found to be statistically significant (p less than .05). Thus, CyA might serve as an important mode of treatment of sensorineural hearing loss on an inflammatory "autoimmune" background.
35例白塞病患者（20例接受环孢素A[CyA]治疗，15例接受传统治疗）、12例内源性葡萄膜炎患者和35名正常受试者在进入研究前接受了听力学评估，并进行了至少一年的随访。28例白塞病患者（80%）出现了一定程度的听力损失。与对照组相比，白塞病组的平均纯音听力图显示出具有统计学意义的听觉缺陷。在随访期间，白塞病组和葡萄膜炎组均未出现听力恶化。5例接受CyA治疗的白塞病患者听力有所改善。发现两组白塞病患者（CyA治疗组与传统治疗组）之间的差异具有统计学意义（p<0.05）。因此，CyA可能作为在炎症性“自身免疫”背景下治疗感音神经性听力损失的一种重要治疗方式。
